VOLUME NO. 7, ISSUE 3 • NOVEMBER 2026

UMAG
MAGAZINE

Members are the Fabric of our Society





Unleashing the power of innovation

At Ferring, we believe in the power of science and are committed to discovering and developing transformational therapies in the area of uro-oncology that help people live better lives.

FERRING and the Ferring Pharmaceuticals logo are trademarks of Ferring B.V.
© 2023 Ferring B.V.
GL-nonP-2300009. Date of preparation : December 2023.

www.ferring.com

Building families and helping people live better lives

FERRING
PHARMACEUTICALS



CONTENTS

05
SIU Governance
Message from the President
2025–2026 Board of Directors

06
SIU Membership
Earn Rewards with SIU Loyalty Programme

07–08
SIU 2026 Congress
Surgery Day Programme
Programme Highlights
8th Bench to Bedside Uro-Oncology: GU Cancers Triad Update

13–14
SIU Office of Education
Coming Soon to SIU Academy
ICUD Publication Update

15
SIUJ
About SIUJ
Editorial Board
SIUJ Awards

16
uCARE
Help Shape the Future of Urological Research

17–19
SIU Institues and Scholarships
Available Scholarships
SIU Scholar Snapshot
SIU Training Centres

20
Sponsor Acknowledgements

UMAG MAGAZINE

The Magazine of the Société Internationale d'Urologie

2026 Photos: SIU Image Bank.
All information published is accurate as of time of publication.


© 2026 Société Internationale d'Urologie

SIU Central Office
1134 Ste-Catherine Street West, Suite 920
Montreal (Quebec), Canada H3B 1H4
Tel: +1 (514) 875-5665 • Fax: +1 (514) 875-0205
communications@siu-urology.org
www.siu-urology.org • #SIUWorld

SIU Around the WORLD FLORENCE 2026

46th Congress of the Société Internationale d'Urologie

November 11–14, 2026



Targeting Prostatic Inflammation in the Management of Male LUTS

SS-01 | **Thursday, November 12** 10:45–11:15 CET | **Room:** Elhilali, Spadolini Building, Ground Floor

Gain Insights Into the Emerging Role of Prostatic Inflammation in Male LUTS

Learning Objectives

At the end of this symposium, participants should be able to:

- Recall the role of prostatic inflammation in the development, progression, and severity of LUTS/BPH.
- Review novel, non-invasive approaches for identifying patients with prostatic inflammation.
- Recognize the implications of prostatic inflammation for guiding treatment decision-making in patients with LUTS/BPH.

Chair



Stavros Gravas
Medical School,
University of Cyprus,
Nicosia, Cyprus

Panel



Cosimo De Nunzio
Department of Urology, Sant'Andrea Hospital,
University La Sapienza,
Rome, Italy



Silvia Secco
Department of Urology,
Niguarda Hospital,
Milan, Italy

This session will be transmitted live via the SIU Congress platform. SIU@U

This symposium is supported by SIU Congress Contributor Pierre Fabre Médicament.

SIU2026Florence • SIUatU



Dear Friends,

I have been actively involved in the SIU for decades, and it is my great honour to represent the Society as President for 2025–2026. I have always valued the SIU's mission to share education and research in a collaborative community, and I look forward to moving this mission forward over the next year.

The SIU ties together many important principles: tradition and innovation, individual contributions and community spirit, celebrating cultural differences alongside shared values. The common thread through all the Society's initiatives and innovations is the focus on improving patient care through advancements in education, training, research, and philanthropy.

I encourage you to browse through this magazine and see which Society initiatives—from online training programmes to research publications to in-person educational activities—resonate the most with you and get involved in whatever capacity works. Let's focus on strengthening our ties, improving our practice, and working together to improve urology around the world.

Your active involvement as a member will now offer you even more benefits through the Society's new loyalty programme; go to page 6 to find out more!

Finally, I offer my sincere gratitude to my colleagues who give so generously of their time and expertise to continue the work of this important organization. Thank you as well to our industry partners who are integral to the success of many Society activities. It takes the contributions of many to build a thriving Society such as the SIU!

William Lynch
SIU President, Australia

2025–2026 SIU BOARD OF DIRECTORS

William Lynch, Australia
President

Yasser Farahat, United Arab Emirates
President Elect

Mihir Desai, United States
Vice President

Jean de la Rosette, Türkiye
Past President and Nominating Committee Chair

Stavros Gravas, Cyprus
General Secretary

Rafael Sanchez-Salas, Canada
Treasurer

Mauro Gacci, Italy
Office of Education

Sung Kyu Hong, South Korea
Office of Research

Vincenzo Ficarra, Italy
Publications

Jeremy Teoh, Hong Kong SAR
Congress Organizing

Athanasios Papatsoris, Greece
Congress Organizing Elect

Steffi Kar Kei Yuen, Hong Kong SAR
Corporate Development

Membership and International Relations

Papa Ahmed Fall, Senegal
Africa and Middle East

Juan Carlos Castaño, Colombia
Americas

Madhu Agrawal, India
Asia-Pacific

Avelino Fraga, Portugal
Europe

Philippe Spiess, United States
Consensus and Education

Dean Elterman, Canada
Innovators

Junhua Zheng, China
Institutes and Scholarships

Seth Lerner, United States
Scientific Programme Co-Chair

Vineet Gauhar, Singapore
Scientific Programme Co-Chair

Francisco J. Sanchez G., Mexico
National Society Delegate Representative

Matin Sheriff, United Kingdom
National Society Delegate Representative

Paksi Satyagraha, Indonesia
General Assembly Representative

Gonzalo Vitagliano, Argentina
General Assembly Representative

EARN REWARDS WITH THE SIU MEMBER LOYALTY PROGRAMME

SIU members can earn points by engaging in various activities across SIU platforms—from participation in committees to paying dues early to attending educational events. Points can be redeemed for exclusive rewards including, but not limited to, free membership, reduced Congress registration fees, and free hotel stays. All SIU members are automatically enrolled in the SIU Membership Loyalty programme.

Membership must be renewed annually to maintain active status and continue earning and redeeming points. Renewal can be completed online through the SIU website. Members who renew early receive additional points as an incentive. For more information, visit siu-urology.org/society/member-loyalty-programme.

Of course, SIU members will continue to enjoy existing benefits such as

- Immediate access to all content on SIU Academy
- Reduced Congress fees
- Global networking opportunities
- Educational events, online and in-person

ENGAGE **EARN** **REDEEM**

DON'T FORGET

Residents and trainees are eligible for free membership!

Find out more about SIU Membership and register today!

Join the SIU mailing list to receive emails on all Society activities.

SURGERY DAY PROGRAMME

Thursday, November 12 | 0715–1730 CET (UTC+1) | Guyon Room, Cavaniglia Pavilion

About Surgery Day

This dynamic, all day session will highlight essential urological procedures in endourology of upper and lower urinary tract, uro-oncology and focal therapy, and reconstruction. Led by internationally renowned experts, the programme will feature real-time transmissions of live surgeries from prominent centres, alongside engaging semi-live presentations. Join us for insights into innovative technologies, advanced instrumentation, and cutting-edge techniques.

Surgery Day will be livestreamed on the *SIU@U* app, included with your Congress in-person and virtual registration.

Surgery Day Planning Committee

Jean de la Rosette, Türkiye

Yasser Faharat, United Arab Emirates

Stavros Gravas, Cyprus

Saad Aldusari, Kuwait

Luca Cindolo, Italy

Ferdinando Fusco, Italy

Rabii Madi, United Arab Emirates

Matin Sheriff, United Kingdom

Guohua Zeng, China

Learning Objectives:

At the end of this session, attendees should be able to:

- Review recent developments in equipment and techniques for the minimally invasive and surgical management of urological diseases, based on surgical demonstrations and expert discussion.
- Discuss the role of open, laparoscopic, and robotic-assisted surgical approaches in uro-oncology and reconstructive urology, including emerging systems, instrumentation, and techniques.
- Summarize practical applications of instrumentation and techniques used in the endourological management of upper and lower urinary tract conditions.
- Describe the role of focal therapy and novel imaging approaches in uro-oncology.
- Identify key perioperative considerations for optimizing outcomes in urological surgery, based on current treatment guidelines and expert opinion.

Watch this session live to claim **CME credits**.

This programme is supported by **SIU Congress Contributors**
Boston Scientific, Dyne Medical Group, Edge Medical, EMS, Fujifilm Europe, Lefkos Stavros - The Athens Clinic, Medtronic, MicroPort, Olympus, Procept BioRobotics, Pusen, Rocamed/Elesta, Roen Surgical, Sofmedica, Sonablate, SS Innovations International Inc., Well Lead Medical Co. Ltd | ClearPetra, ZSR.

SIU Around the WORLD FLORENCE 2026

46th Congress of the Société Internationale d'Urologie

November 11–14, 2026

PROGRAMME HIGHLIGHTS

THURSDAY, NOVEMBER 12

Surgery Day

0715-0845 **Session 1:** Endourology

1115-1245 **Session 2:** Uro-Oncology

1345-1530 **Session 3:** Endourology and Reconstructive Surgery

1540-1730 **Session 4:** Lower Urinary Tract, Uro-Oncology, and Reconstructive Surgery

Industry Symposia

1045-1115 **Morning Symposium:** Targeting Prostatic Inflammation in the Management of Male LUTS

Workshops

1100-1300 DISS Training for Stone Management

1100-1500 Prostate MRI & Transperineal Prostate Biopsy Course

1330-1730 Prostate MRI & Transperineal Prostate Biopsy Course

1530-1730 Suction, Irrigation and Pressure-Regulating Systems (SIPS) in Flexible Ureteroscopy



FRIDAY, NOVEMBER 13

Industry Symposia

1000-1030 **Morning Symposium:** The Evolving Role of ß3 Agonists in the Management of Male LUTS

B2B Uro-Oncology: GU Cancers Triad Meeting

1000-1150 Bladder Cancer

1200-1245 **B2B Luncheon Symposium:** Understanding the Urologist's Role in the Contemporary Management of mCRPC

1200-1245 **B2B Luncheon Symposium:** Biomarker-Driven Therapies: Towards Precision Medicine in Advanced Urothelial Carcinoma

1250-1430 Kidney Cancer

1435-1615 Prostate Cancer

1620-1725 Practice-Changing Advances on the Horizon

Workshops

1015-1215 Laparoscopy for Beginners

1430-1630 Laparoscopy for Beginners

SATURDAY, NOVEMBER 14

Workshop


1100-1300 Lasers & MISTS in LUTS/BPH



SIU Around the WORLD FLORENCE 2026

46th Congress of the Société Internationale d'Urologie

November 11–14, 2026



The Evolving Role of β3 Agonists in the Management of Male LUTS

SS-02 | **Friday, November 13** • 10:00–10:30 CET

Rochford Room, Spadolini Building, Ground Floor

How to Integrate β3 Agonists into the Management of Men With Moderate-to-Severe Storage LUTS?

Learning Objectives

At the end of this symposium, participants should be able to:

- Recognize the importance of managing storage symptoms in men with male LUTS.
- Evaluate efficacy and safety data supporting the use of β3 agonist monotherapy for the management of male patients with storage-predominant LUTS.
- Assess current guideline recommendations with respect to the use of β3 agonists in male LUTS.
- Examine management approaches for men with moderate-to-severe storage symptoms from diagnosis to treatment, with the aim to individualize patient care.

Chair



Dean Elterman
Division of Urology, Department of Surgery,
University of Toronto,
Toronto, Canada

Panel



Cosimo De Nunzio
Department of Urology, Sant'Andrea Hospital,
University La Sapienza,
Rome, Italy



Sandra Elmer
Department of Urology,
The Royal Melbourne Hospital,
Melbourne, Australia

This session will be transmitted live via the SIU Congress platform. SIU@U

This symposium is supported by SIU Congress Contributor Astellas Pharma Europe Ltd.

SIU2026Florence • SIUatU

B2B Scientific Programme Committee



Peter C. Black
Canada



Silvia Secco
Italy



Simon Tanguay
Canada

BENCH TO BEDSIDE
URO-ONCOLOGY
GU CANCERS TRIAD

In conjunction with SIU Around the WORLD FLORENCE 2026
November 11–14

Friday, November 13, 2026 • 1000–1725 CET
Room: Elhilali Room, Spadolini Building, Ground Floor

The B2B Meeting will be livestreamed on the *SIU@U* app, included with your Congress registration.

ABOUT THE MEETING

Watch world-renowned experts present the latest advances in the management of the three most prevalent GU cancers: bladder, kidney, and prostate. Interact with the faculty and participate in dynamic discussions on evolving clinical practices.

LEARNING OBJECTIVES

At the end of this programme, participants will be able to:

- Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
- Recognize the role of imaging and genetic markers in guiding treatment decision-making.
- Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
- Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
- Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

MAKE SURE TO ATTEND

B2B Luncheon Symposium:
Biomarker-Driven Therapies: Towards Precision Medicine in Advanced Urothelial Carcinoma

Friday, November 13, 2026 • 12:00–12:45 CET
Rochford Room, Spadolini Building, Ground Floor

Daiichi Sankyo | AstraZeneca has provided a sponsorship grant towards this independent programme.

B2B Luncheon Symposium:
Understanding the Urologist's Role in the Contemporary Management of mCRPC

Friday, November 13, 2026 • 12:00–12:45 CET
Elhilali Room, Spadolini Building, Ground Floor

This independent symposium is supported by an unrestricted grant from Bristol Myers Squibb.

Watch these sessions live to claim **CME credits**.

The B2B Uro-Oncology: GU Cancers Triad Meeting is supported by:
B2B Presenting Sponsors: Daiichi Sankyo | AstraZeneca, Bristol Myers Squibb, and Ferring Pharmaceuticals
B2B Contributing Sponsors: CG Oncology, Johnson & Johnson, and Merck Sharp & Dohme LLC

BENCH TO BEDSIDE
URO-ONCOLOGY
GU CANCERS TRIAD

SIU Around the WORLD FLORENCE 2026

46th Congress of the Société Internationale d'Urologie
November 11–14, 2026



Biomarker-Driven Therapies:

Towards Precision Medicine in Advanced Urothelial Carcinoma

B2B-02.1

Friday, November 13 • 12:00–12:45 CET

Rochford Room, Spadolini Building, Ground Floor

Explore Biomarker-Driven Therapies in Advanced Urothelial Cancer

Learning Objectives

At the end of this symposium, participants should be able to:

- Recognize the role of biomarker-driven treatment strategies in advanced urothelial carcinoma, including the strengths and limitations of existing predictive biomarkers.
- Evaluate clinical evidence for approved and emerging FGFR- and HER2-targeted therapies.
- Identify biomarker-guided approaches for treatment selection and sequencing in patients with advanced urothelial carcinoma, including challenges for implementation in clinical practice.

Chair



Kilian Gust
Department of Urology, Comprehensive Cancer Center,
Medical University of Vienna,
Vienna, Austria

Speakers



Karima Oualla
Department of Medical Oncology,
Hassan II University Hospital,
Fez, Morocco



Daniele Raggi
Genitourinary Oncology,
The Royal Marsden NHS Foundation Trust,
London, United Kingdom

This session will be transmitted live via the SIU Congress platform. SIU @ U

Daiichi Sankyo | AstraZeneca has provided a sponsorship grant towards this independent programme.

SIU2026Florence • SIUatU


SIU Around the World Florence 2026

46th Congress of the Société Internationale d'Urologie

November 11–14, 2026

B2B BENCH TO BEDSIDE URO-ONCOLOGY GU CANCERS TRIAD

Understanding the Urologist's Role in the Contemporary Management of mCRPC



SIU@U

B2B-02.2

FRIDAY, NOVEMBER 13 • 12:00–12:45 CET

Elhilali Room, Spadolini Building, Ground Floor

Explore the Urologist's Evolving Role in mCRPC Management

Learning Objectives

At the end of this symposium, participants should be able to:

- Assess the clinical impact of PSMA PET/CT on staging, risk stratification, and treatment selection.
- Apply genetic testing to support individualized treatment decision-making for patients with advanced prostate cancer.
- Evaluate contemporary systemic therapies for mCRPC along with biomarker-driven approaches to guide treatment selection.
- Recognize the evolving role of urologists within a multidisciplinary care team managing patients with metastatic prostate cancer.

Chair



Sung Kyu Hong
Department of Urology,
Seoul National University College of Medicine,
Seoul, Korea

Speakers



Leonard Gomella
Department of Urology,
Thomas Jefferson University,
Philadelphia, United States



Peter Hammerer
Department of Urology and Uro-Oncology,
Academic Hospital Klinikum Braunschweig,
Braunschweig, Germany



Elio Mazzone
Department of Urology,
ASST Grande Ospedale Metropolitano Niguarda,
Milan, Italy

This session will be transmitted live via the SIU Congress platform. SIU@U

This independent symposium is supported by an unrestricted grant from Bristol Myers Squibb.

SIU2026Florence • SIUatU

COMING SOON TO SIU ACADEMY

TWO NEW CME-ACCREDITED COURSES

Bladder and Upper Urinary Tract TCC Subcommittee

Selecting Therapies in HR-NMIBC

The contemporary management of NMIBC follows a risk adapted approach. In patients with high-risk disease, treatment usually consists of TURBT followed by intravesical BCG and 3 years of BCG maintenance. Focusing on clinical cases, this course will provide you with a guideline-based overview of the management of HR-NMIBC from initial assessment and risk stratification through treatment selection and follow-up as well as approaches for patients who do not respond to BCG therapy or recur after initial response to BCG.



Marco Moschini,
MD PhD
Italy



Giovanni Tremolada,
MD
Italy

Infection and Inflammation Subcommittee

Management of Refractory Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS) is a chronic, debilitating, and one of the most challenging conditions in urological practice. As biopsychosocial disorder, IC/BPS requires a multidisciplinary management in which urologists play an intrinsic role. This course will provide you with an overview of IC/BPS pathophysiology as well as practical guidance for management of treatment-naive and treatment-refractory IC/BPS through compelling clinical cases.



Meghan Cooper,
DO MA
United States



Marilin Nicholson,
MD
United States

GrandRounds

Watch the final eGrand Rounds of 2026:
Update in BPH Management. Wednesday, December 2, 2026 0900–1230 CET (UTC+1):
Register Today

Revisit eGrand Rounds On Demand
Update in Stone Management – April 29, 2026
Watch Here

Update in Urothelial Cancer Management
September 23, 2026:
Watch Here

ACADEMY AWARDS FOR OUTSTANDING CONTENT

Most Viewed in 2025 for the eGrand Rounds

Update in Stone Management – February 12, 2025
Jean de la Rosette, Leye Ajayi, Vitor Cavadas, Vincent De Coninck, Wojciech Krajewski, Davide Perri

Update in BPH Management – May 7, 2025
Jean de la Rosette, Gian Maria Busetto, Cecilia Maria Cracco, Stavros Gravas, Thomas Herrmann, Karin Lehrich

Most Viewed in 2025 for the Congress Symposium

Morning Symposium: Suction in Endourology – More than Just Suction, Understanding Fluid Dynamics – October 30, 2025
Steffi Kar Kei Yuen, Vineet Gauhar, Jia-Lun Kwok, Bhaskar Somani

UROTRAINER

STAY TUNED FOR MORE UROTRAINER EDUCATIONAL PROGRAMMES COMING IN 2027.
www.urotrainer.com

These educational programmes were supported by SIU Corporate Sponsor Karl Storz.

PUBLICATION



SIU-ICUD Consultation on Individualized Management of Male LUTS

Led by the co-editors Prof. Stavros Gravas, Dr Dean Elterman, and Prof. Andrea Tubaro, this SIU-ICUD Consultation represents **the very first publication dedicated to the *individualized management* of male LUTS** as well as the first attempt of adopting the concept of personalized medicine in chronic benign diseases or conditions in urology.

Expert-led committees comprising global thought leaders in male LUTS produced comprehensive review chapters on the most pertinent topics in patient management. In each chapter, you will find practical recommendations for the individualized management of male LUTS developed using both levels of evidence and grades of recommendation according to the ICUD Modified Oxford Centre for Evidence-Based Medicine Grading System.



Stavros Gravas
Cyprus, Co-Editor



Dean Elteman
Canada, Co-Editor



Andrea Tubaro
Italy, Co-Editor

Accessible on SIU Academy—no login required. Read and download the latest SIU-ICUD Consultation, watch the webcast to get insights from Co-Editors and Committee Chairs, and explore online procedural videos on surgical and minimally invasive treatments for male LUTS.

Chapters and Chairs

Lower Urinary Tract Symptoms in Men
Karel Everaert, Belgium
Philip van Kerrebroeck, Netherlands

Patient Assessment
Marcus Drake, United Kingdom

Lifestyle Intervention and Pharmacological Treatments
Andrea Tubaro, Italy

Invasive Surgical Treatments
Peter Gilling, New Zealand
Henry Woo, Australia

BPH Minimally Invasive Treatments
Bradley Gill, United States
Kevin Zorn, Canada

Predictive Models—Nomograms for Patient Outcome and Success Criteria
Stavros Gravas, Cyprus

Managing Patients with Complications and Persistent Symptoms
Enrico Finazzi Agrò, Italy

Algorithms for the Management of Male LUTS
Dean Elterman, Canada, Stavros Gravas, Greece, Andrea Tubaro, Italy

The SIU-ICUD Individualized Management of Male LUTS was supported by Boston Scientific, GSK, Laborie, Pierre Fabre Laboratoires, PROCEPT BioRobotics, and Teleflex.

DUOMO


SIUJ | Société Internationale d'Urologie Journal

The *Société Internationale d'Urologie Journal (SIUJ)* is an international, peer-reviewed, open access journal that covers all aspects of urology and related fields. The Journal is owned by the SIU and is published every two months online by MDPI.

Open Access
Free for readers and authors (diamond open access).

Rapid Publication
Manuscripts are peer-reviewed and a first decision is provided to authors approximately 51.2 days after submission; acceptance to publication is undertaken in 34.2 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers
APC discount vouchers, optional signed peer review, and reviewer names published annually in the Journal.



Journal Awards

Best Paper Award
The *SIUJ Best Paper Award* is granted annually to highlight publications of a high quality with scientific significance and a significant impact. This year, the evaluation committee will choose article(s) published in the Journal from July 1, 2025, to June 30, 2026.

Outstanding Reviewer Award
The *Outstanding Reviewer Award* is given annually at the SIU Congress to recognize reviewers who generously contribute their time to reviewing papers and display thoroughness, professionalism, and timeliness.

CONGRATULATIONS TO THIS YEAR'S WINNERS



Outstanding Reviewer Award
Abdullah Erbem Canda, Türkiye



Best Paper Award
Alberti Andrea, Italy

EDITORIAL BOARD


Henry Woo
Editor-in-Chief, Australia


Peter C. Black
Editor Emeritus, Canada

ASSOCIATE EDITORS


Lysanne Campeau
Canada


Sanjay Sinha
India


Steffi Kar Kei Yuen
Hong Kong SAR

Subscribe via www.mdpi.com/journal/siuj to receive the eTOC for each issue and stay up to date on the latest content highlights via the *SIUJ* social media channels (X @SIU_Journal & LinkedIn).

Share your research with colleagues around the world by submitting to *SIUJ* via MDPI at the link above.

uCARE Collaborative Applied Research



Sung Kyu Hong
South Korea
Chair, Office of Research

Help Shape the Future of Urological Research

uCARE is the Société Internationale d'Urologie's official Office of Research, created in the fall of 2017. uCARE generates opportunities for clinicians to participate in clinical studies and contribute to knowledge development and translation in urology. Join a global community of urologists, patients, and organizations committed to urological research.

There is still an opportunity to join the BPH Global Registry. Find out more and register your institution: www.siu-urology.org/ucare/submit-your-institution

AN UPDATE ON THE BPH GLOBAL REGISTRY

151
Centres recruited

1350
Patients enrolled

34
Centres with IRB approval

Scholarships

Apply for SIU Scholarships and share with colleagues!

SIU Training Scholarships

The SIU offers two types of training scholarships. Urologists from the developing world who have completed their urology specialization within the past five years* are eligible to apply.

- The first scholarship allows the scholar to train in an SIU-Accredited Training Centre in the candidate's geographical area.
- The second scholarship grants the visiting scholar an observational role in an SIU-Accredited Training Centre.

Both programmes offer scholarships for surgeons for a 3- or 6-month period in an SIU-recognized institute, with US $5,000 for a 6-month period and US $2,500 for a 3-month period.



SIU-PAUSA Scholarship

The SIU and the Pan-African Urological Surgeons' Association (PAUSA) have partnered to offer a training scholarship for young urologists (within 5 years of obtaining their urology specialization*) from Africa.

This scholarship will provide young urologists with an opportunity to enhance their skills by completing training in a non-African country. Each year, SIU and PAUSA grant one **6-month scholarship of US $5,000** to one applicant.

**Please note that this criterion has changed from 10 years post-MD to 5 years post urology certification.*



Mohammed Ali Saeed, Yemen

SIU Scholar Snapshot

"The mentorship from Dr. Rawal has exceeded my expectations, with detailed guidance in clinical and surgical care, encouraging full involvement in every aspect of oncologic management. Integration of hospital-based training with external robotic simulation practice has accelerated my learning beyond initial expectations."

MAY 31, 2027, IS THE APPLICATION DEADLINE FOR ALL SIU SCHOLARSHIPS*

Visit **www.siu-urology.org/training-schol/applyscholarship** and look under **"Training Scholarships"** or email us at **central.office@siu-urology.org** for full details and requirements.



ANNOUNCING THE SIU-PAUSA TRAINING SCHOLARSHIP

Calling all Early Career Urologists from Africa!

The Société Internationale d'Urologie (SIU) and the Pan-African Urological Surgeons' Association (PAUSA) are collaborating to offer a joint scholarship to provide young urologists with an opportunity to enhance their skills.

- One scholarship available per year.
- Duration of the scholarship is 6 months.
- Available to young urologists from Africa within 5 years of obtaining their urology specialization.
- Amount of the scholarship **5,000 USD**.
- Scholarship at an SIU-accredited training centre located in non-African countries.

Application Deadline: May 31, 2027

To apply, visit **www.siu-urology.org** and complete the online application form.

SIU Training Centres

For full training centre details, please visit the SIU website: **siu-urology.org/society/trainingcentre**.

ARGENTINA

Hospital de Clínicas José de San Martín
www.hospitaldeclinicas.uba.ar
Programme Director: Norberto Bernardo

CHILE

Clínica Indisa
Programme Director: Octavio Castillo
www.indisa.cl
dr.octaviocastillo@gmail.com

Hospital del Trabajador
Programme Director: Reynaldo Gómez
gomez.reynaldo@gmail.com

CHINA

The First Affiliated Hospital, Zhejiang University
www.zju.edu.cn
Programme Director: Liping Xie
xielp@zju.edu.cn

The Third Affiliated Hospital of Sun Yat-Sen University
www.zssy.com.cn
Programme Director: Xiangfu Zhou
xiangfuzhou@126.com

First Affiliated Hospital of Medical College of Xi'an Jiaotong University
www.med.xjtu.edu.cn
Programme Director: Lei Li
lilydr@163.com

COLOMBIA

Universidad CES
www.ces.edu.co
Programme Director: Rafael Castellanos Acosta
ricastellanos@ces.edu.co

EGYPT

University of Alexandria
www.med.alexu.edu.eg
Programme Director: Wael Sameh
alexuro@alexmed.edu.eg

GERMANY

Universitaetsklinikum Hamburg-Eppendorf
www.uke.de/index.html
Programme Director: Margit Fisch
m.fisch@uke.de

INDIA

Medanta – The Medicity, Medanta Kidney & Urology Institute
www.medanta.org/kidney-hospital
Programme Director: Narmada Prasad Gupta
narmadagupta@gmail.com

Muljibhai Patel Urological Hospital
www.mpuh.org
Programme Director: Akshaya Kiledar
akshaya.kiledar@mpuh.org

Rajiv Gandhi Cancer Institute and Research Centre
www.rgcirc.org
Programme Director: Sudhir Rawal
info@rgcirc.org

Sanjay Gandhi Postgraduate Institute of Medical Sciences
https://sgpgims.org.in/
Programme Director: MS Ansari
ansarimsa@hotmail.com

UROKUL Pune/Kulkarni UroSurgery Institute Pvt Ltd
https://strictureurethra.in
Programme Directors: Sanjay Kulkarni and Pankaj Joshi
urokul22@gmail.com / drpankajmjoshi@gmail.com

ITALY

Bambino Gesù Pediatric Hospital
www.ospedalebambinogesu.it
Programme Directors: Giovanni Mossiello and Massimiliano Silveri
giovanni.mosiello@opbg.net / massimiliano.silveri@opbg.net

KENYA

East Africa Kidney Institute
https://eaki.uonbi.ac.ke
Programme Director: Peter Mungai Ngugi
eaki@uonbi.ac.ke

Agha Khan University Hospital
https://hospitals.aku.edu/nairobi/Pages/default.aspx
Programme Director: Ahmed A. Yousef

NIGERIA

PIUTA Ibadan Center
https://eaki.uonbi.ac.ke
Programme Director: Oluwabunmi Olapade-Olaopa
Info.piutaibadan@yahoo.com

PAKISTAN

Institute of Kidney Diseases, Peshawar
https://www.ikdpeshawar.gkp.pk/
Programme Director: Muhammad Kamran Khan
director@ikdpeshawar.gkp.pk

RUSSIA

Moscow Urology Center, Botkin Hospital
Programme Director: Dmitry Pushkar
Pushkarmd@mail.ru

SOUTH AFRICA

University of Cape Town
www.uct.ac.za
Programme Director: John Lazarus
j.lazarus@uct.ac.za

University of Stellenbosch & Tygerberg Hospital
www.sun.ac.za/english
Programme Director: Andre van der Merwe
arvdm@sun.ac.za

SPAIN

Hospital Clinico San Carlos
https://www.comunidad.madrid/hospital/clinicosancarlos/
Programme Director: Jesus Moreno Sierra
urolog.hcsc@salud.madrid.org

TANZANIA

Institute of Urology at KCMC
www.kcmc.ac.tz
Programme Director: Kien Alfred Mteta
akamteta@hotmail.com

TUNISIA

University Sahloul Hospital
Programme Director: Wissem Hamida
hmidawissem@gmail.com

SPONSOR ACKNOWLEDGEMENTS

The Société Internationale d'Urologie would like to thank its industry partners for the continued support.

CORPORATE SPONSORS

FERRING PHARMACEUTICALS

STORZ KARL STORZ — ENDOSKOPE

PRESENTING SPONSORS

Daiichi-Sankyo | AstraZeneca | Bristol Myers Squibb® | FERRING PHARMACEUTICALS

CONGRESS CONTRIBUTORS

accord We make it better

A.MENARINI diagnostics

astellas

BIOBOT

Bio-STILOGIT PHARMACEUTICALS

Boston Scientific Advancing science for life™

CARBON

CG ONCOLOGY Attacking Bladder Cancer for a Better Tomorrow™

DEKA Innate Ability

DYNE MEDICAL GROUP INC

EDGE MEDICAL

EMS

EXACT IMAGING

fidia

Focal One ROBOTIC FOCAL HIFU

FUJIFILM

Johnson&Johnson

KALTEQ

Laborie FOR DIGNITY. FOR LIFE.

LAMPUGNANI FARMACEUTICI S.p.A

LEFKOS STAVROS

Medtronic Engineering the extraordinary

MicroPort | Tsunami Hope of Life

MSD

OLYMPUS

LABORATOIRES Pierre Fabre New ways to care

PROCEPT BioRobotics

PUSEN®

ROCAMED

ROEN SURGICAL

S&R FARMACEUTICI

SOFMEDICA LIFE SAVING INNOVATION

sonablate HIFU

SSii

UROLIFT™ | Barrigel™

wellead®

ZSR®

SAVE THE DATE

SIU Around the WORLD

HONG KONG 2027

October 20–23



SOCIÉTÉ INTERNATIONALE D'UROLOGIE • SIU •

siu-urology.org



www.siu-urology.org